Engineering the Future of Blood
Rednova is a US-based biotechnology company developing an engineered human cell platform designed to produce lab-grown red blood cells. Our aim is to establish a renewable source of red blood cells that accelerates drug discovery and enables the future biomanufacturing of human blood. We are building the foundation for a future in which blood can be manufactured rather than solely donated.
Why It Matters
Today’s blood supply faces structural constraints that create recurring shortages and safety burdens.
Blood supply is limited and uneven worldwide, and shortages can occur even in well-resourced systems when donations drop or demand spikes.
Certain blood types are persistently constrained—especially O negative, which is essential for emergencies but relatively rare.
Patients who require repeated transfusions (e.g., many people with sickle cell disease) face alloimmunization, making it harder and harder to find compatible units and increasing complication risk.
Donor-derived blood requires extensive screening to reduce the risk of blood-borne pathogens (including HIV), which adds significant cost and operational complexity.
Our Technology
Our technology in a nutshell
An engineered inducible, immortalized erythroid progenitor platform designed to provide a renewable cell source for lab-grown human red blood cells for transfusion applications and disease modeling.
What we’re building
An engineered, bankable erythroid progenitor cell source
A foundation for manufacturing rare and ultra-rare blood types (e.g., O negative)
A gene-editing–compatible platform for disease modeling
A platform for drug screening and assay development
A development path toward donor-independent transfusion
Donor-derived progenitor cells
Rednova Erythroid Platform
Rednova is developing an inducible, immortalized erythroid progenitor platform to enable lab-grown human red blood cells for transfusion. Many efforts in the field rely on donor-derived hematopoietic stem cells, which are inherently donor-dependent—introducing variability in expansion behavior and requiring repeated verification of product quality and antigen profiles across donors and lots. Because erythroid progenitors are downstream of stem cells, a progenitor-based strategy provides a more direct route to red blood cell production and can reduce process complexity and cost. By engineering erythroid progenitors into a renewable and bankable cell source, Rednova aims to establish consistent red blood cell production and expand access to rare blood types, including O negative, for emergency and chronically transfused patient needs. The platform is intended to be compatible with gene editing approaches, including CRISPR, enabling disease modeling, drug discovery, and process development.
Rednova is an early-stage company actively exploring seed funding and strategic partnerships. We welcome conversations with incubators, investors, and collaborators.